AUTHOR INDEX

Volume 33, 1995

Aalto, Y., 297
Abbruzzese, J.L., 913
Abe, H., 323
Abe, M., 119
Abellera, M., 1009
Adair, T., 461
Addison, H., 797
Adolph, J., 307
Agresti, R., 59
Ahmad, N.R., 837
Aird, E.G.A., 549, 563
Algan, Ö., 925
Al-Sarraf, M., 761
Amols, H., 225
Ando, K., 135
Ang, K.K., 289, 529
Anscher, M.S., 37
Arias, F., 675
Arnfield, M.R., 931
Asbell, S.D., 823
Asselain, B., 271
Atari, N.A., 931
Austin-Seymour, M., 1041, 1073

Babb, J.S., 111
Balter, J.M., 1281
Beard, C., 901
Beattie, E.J., 183
Beinfield, M., 53
Belkacemi, Y., 951
Bell, R., 689
Bentel, G., 65
Bentel, G.C., 1209
Bentzen, S.M., 755
Berberich, W., 349
Bergman, K.S., 391
Berson, A.M., 183
Biade, S., 111
Bidmead, M.A.M., 549, 563
Biggs, P.J., 725
Blair, J.R., 659
Blaszka, B., 271
Bleasdale, C., 195
Blitzer, P.H., 329
Blond, S., 201
Boccardo, F., 173
Bornstein, B.A., 245
Bosworth, J., 851
Bourge, R.C., 83
Boxwala, A., 1287
Boyer, A.L., 1053
Brabbins, D., 1019, 161
Brada, M., 769
Brahme, A., 151
Bree, R.L., 1281
Brewster, L., 1081
Brown, D., 1019
Brown, D.Q., 111
Brown, L.D., 663
Brown, S.L., 861
Bruce, A., 1311
Bruce, A.M., 1109
Brugere, J., 271
Bruner, J., 357
Brunin, F., 271
Buchholz, D.J., 913
Bujnowski, S.W., 1127
Bünemann, H., 77
Burman, C., 1081
Buswell, L., 901
Byrne, K., 179

Campbell, I.L., 619
Canobbio, L., 173
Carosella, E., 881
Castelain, B., 201
Catton, C., 689
Caudry, M., 315
Causse, N., 315
Célérier, D., 315
Cella, D., 901
Chaillet, M.-P., 881
Chan, A.T.C., 569
Chan, M.S.Y., 919
Chaney, E.L., 1287
Chao, C.K.S., 831
Chapman, J.D., 111
Chappell, R., 509
Chawla, K., 1273
Chen, G., 1001
Chen, G.T.Y., 1009, 1041, 1121, 1221, 1321, 979
Chen, W., 683
Chiang, C.-S., 619
Childress, C., 479
Chinn, D.M., 15
Chiru, P., 1009
Chodak, G.W., 3
Choi, P.H.K., 569
Chon, Y., 549, 563
Chow, J.H.S., 919
Chu, J.C.H., 683
Clave, E., 881
Cleary, K.R., 913
Clough, R., 65
Cohen, D., 129
Cohen, L., 217
Coia, L.R., 695
Coleman, C.N., 531
Coleman, R.E., 65
Colgan, J.P., 663
Collier, C., 913
Constantinidis, I., 143
Corn, B.W., 837
Cosset, J.-M., 271, 881
Cottier, B., 195
Cox, J.D., 179, 747
Cox, R.S., 887
Crownover, R.L., 15
Curotto, A., 173
Dahl, R.A., 725
Daly, W., 579
Das, I.J., 695
Das, S., 1209
Dautheribes, M., 315
Davis, A., 689
DelRowe, J., 901
Denham, J.W., 943
Dewey, W.C., 781
Dewhirst, M.W., 627, 963
Dillehay, L.E., 417
Dische, S., 549, 563
Dobelbower, R.R., Jr., 725
Dodge, R., 627
Dominique, C., 951
Domínguez, M.A., 675
Domínguez, S., 675
Dong, L., 1053
Dopke, K.P., 549, 563
Dosoretz, D.E., 329
Douple, E.B., 641
Du, M., 1229, 1247
Dubray, B., 271
Duchesne, G.M.
Dueñas, M., 675
Dujovny, M., 1221
Dusenbery, K.E., 475

Earle, J.D., 663
Earnhart, J.R.D., 1287
Edmundson, G., 1019, 161
Edmundson, G.K., 1257
Efird, J., 579
Efird, J.T., 585
Elcarte, F., 675
El-Khatib, E., 469, 493
Emami, B., 993
Erdmann, J., 307
Essers, M., 1265
Evans, D.B., 913
Evans, M.L., 391
Ewton, J.R., 1127

Fagundes, M.A., 579
Fenn, J.O., 647
Fenning, M.C., 111
Fenoglio, C.J., 913
Fenton, B.M., 365
Finkelstein, J.N., 99
Fischer, D., 53
Fishman, E.K., 1029
Fleischman, E., 1101
Flentje, M., 307, 455
Flickinger, J.C., 437
Floody, P.A., 329
Fontenla, E., 1321
Forman, J., 797
Forman, J.D., 1321
Forman, S.J., 189
Fornasier, V., 689
Forsgren, S., 297
Foulquier, J.N., 951
Fowble, B., 535
Fowble, B.L., 45
Fowler, J.F., 509, 759
Fraass, B.A., 1061, 1139, 1159, 1173, 1181
Franzén, L., 297
Franzone, P., 173
Frazier, A., 1229, 1247
Freestone, G., 195
Freytag, S.O., 861
Fridman, H., 881
Fritsch, D.S., 1287
Fuks, Z., 1081
Furusawa, Y., 135

Gabarda, A.L., 329
Gage, I., 245
Gal, D., 851
Gall, K.P., 1239
Gamcsik, M.P., 143
Gannett, D., 461
Garden, A.S., 179, 289, 479
Gelman, R., 245
Gentry, L.L., 659
Gerber, R.L., 803
Gerbi, B.J., 475
Gibon, D., 201
Gieschen, H.L., 931
Girinsky, T., 881
Giudici, S., 173
Giuliani, L., 173
Gleason, M.J., 357
Gluckman, E., 881
Goepfert, H., 289
Goitein, M., 1041
Goldsmith, B.J., 765
Gonzalez, J., 1019, 161
Graham, M., 1301
Graham, M.M., 391
Graham, M.V., 993
Greco, M., 59
Griem, K., 683
Grierson, J.R., 391
Griffin, T.W., 231, 391
Griffiths, J.R., 855
Grob, E., 211
Guarneri, D., 173
Guérin, J., 315
Gupta, N., 549, 563
Gustafson, G., 1019, 161
Gustafsson, H., 297

Haffty, B.G., 53
Hall, E.J., 225
Hallahan, D., 261
Halpern, H., 607
Halverson, K., 1301
Hamilton, A., 461

Hamilton, C.S., 943
Hamilton, R.J., 1009, 1221
Hammond, E.H., 823
Hanks, G., 803
Hanks, G.E., 111, 519, 549, 563, 809, 925
Hanley, J., 1331
Hanlon, A., 519, 803
Hanlon, A.L., 549, 563
Hanlon, A.M., 809
Hansen, S.W., 595
Haraf, D.J., 3, 1121
Harms, W., 1301
Harms, W.B., 1195, 985, 993
Harris, J.R., 245
Hart, L.L., 329
Hartmann, G.H., 485
Hartsell, W.F., 683
Harvey, J., 183
Harwin, W.N., 329
Hazle, J.D., 725
He, T., 1321
Hei, T.K., 225
Heilmann, H.-P., 77
Helweg-Larsen, S., 595
Henk, J.M., 549, 563
Henriksson, R., 297
Hensley, F., 455
Hida, K., 323
Higashi, M., 843
Ho, S.K.W., 919
Hoffmann, U., 485
Hoffstetter, S., 447
Hogstrom, K.R., 479, 1127
Holland, J., 15
Hollander, J., 161
Hong, J.-H., 619
Hoogervorst, B.R., 1265
Hoppe, R., 519
Houghton, A., 607
Howe, F.A., 855
Huang, D.T., 281
Hug, E.B., 579, 585
Hughes, D.B., 519
Humm, J.L., 1101
Hummel, S., 1073
Huq, M.S., 725, 937
Hussein, S., 469, 493
Hutchinson, L.K., 875

Ianuzzi, C., 815
Ignacio, L., 607
Illarramendi, J.J., 675
Inada, T., 135
Iwai, H., 119
Iwasaki, Y., 323

Jackson, M., 1239
Jacky, J., 1073
Jacobs, R., 1001
Jaffray, D. A., 1273
Jaszczak, R., 65
Jaulerry, C., 271
Jenrette, J.M., III, 647
Johansson, R., 719
Johnson, C.R., 281
Johnson, P.J., 569, 919
Johnston, C.J., 99
Jones, B., 195
Jones, C.U., 549, 563
Joyce, M., 1247

Kalet, I., 1073
Kamada, T., 323
Kanai, T., 135
Kanazawa, K., 843
Kapp, D.S., 887
Karger, C.P., 485
Karlsson, U., 705
Katin, M.J., 329
Kauppinen, R., 719
Kavanagh, B.D., 931
Keane, T., 549, 563
Kennaugh, R.C., 217
Keraudy, K., 951
Kessler, M.L., 1061, 1139, 1159, 1173, 1181
Kesteloot, K., 499
Khandelwal, S.R., 931
Kiani, M.F., 365
Kim, G.E., 869
Kim, J.H., 861
Kim, O.B., 861
Kim, S.H., 861
Kimura, H., 627
Kirby, T., 705
Kirklin, J.K., 83
Kjörell, U., 297
Klein, E.E., 1195
Klitzman, B.M., 627
Koh, W.-J., 391
Koike, S., 135
Kolozsvary, A., 861
Komaki, R., 179
Kondziolka, D., 437
Koyanagi, I., 323
Krigel, R.L., 663
Kroes, A.P.G., 1109, 1311
Krohn, K.A., 391
Kromhout-Schiro, S., 1073
Kron, T., 943
Krossnes, B.K., 409
Kubota, N., 135
Kuchnir, F.T., 3, 1221
Kumar, S.V., 1321
Kurtz, J.M., 211, 713
Kuszyk, B.S., 1029
Kutcher, G.J., 1331
Kyritsis, A.P., 357

Lai, P.P., 831
Lam, C.F., 647
Lam, K.L., 1281
Lam, K.S., 1091
Lanciano, R.M., 111
Lanciano, R.M., 837
Lane, R.G., 1091
Langer, M., 1091
Lankford, S.P., 907
Lanson, H., 1265
Lapeyre, M., 447
Laramore, G.E., 231
Lau, W.-Y., 919
Lavin, M.F., 129
Lawton, C., 901
Lebesque, J.V., 1109, 1311
Lee, S.P., 375
Lee, W.Y., 569
Leeds, N., 357
Lefkopoulos, D., 951
Leibel, S., 1081
Leibel, S.A., 339
Lescrainier, J., 951
Leu, M.Y., 375
Leung, S.F., 569
Leung, T.W.T., 569, 919
Levin, V.A., 357
Levine, G., 437
Lewellen, T.K., 391
Lewis, J.D., 1139, 1159, 1181
Li, A.K.C., 919
Li, S.-D., 1121
Lichter, A., 797
Lichter, A.S., 253
Liebsch, N.J., 579
Lindsley, K., 1041
Lindsley, K.L., 391
Ling, C.C., 235, 781
Lionberger, M., 705
Littles, J.F., 1281
Loeffler, J.S., 531, 765
Lorenz, W.J., 485
Lovecchio, J., 851
Low, D.A., 1127, 1195
Lu, Y., 1121
Luini, A., 59
Lulu, B., 461
Lunsford, L.D., 437

Mackensen, D.G., 417
Mageras, G., 1081
Mageras, G.S., 1331
Maire, J.-P., 315
Mak, A.C., 289
Malamud, S., 183
Malissard, L., 447
Malone, S., 689
Manzari, A., 59
Maor, M.H., 357
Marchandise, X., 201
Mariani, L., 59
Marks, L.B., 65, 1209
Martin, S.G., 225
Martinez, A., 1019, 1229, 1247, 161
Martinez, A.A., 1257
Martínez, E., 675
Martorana, G., 173
Mathiot, C., 881
Matrone, G.M., 1139, 1159, 1181
Matsubara, S., 135
Matter, R., 1229, 1247
Matthews, J.W., 993
Mauch, P., 959
Mayer, R., 417
McAuliffe, M.J., 1287
McBride, W.H., 233, 375, 619
McCleod, M.J., 329
McCormick, B., 59
McCullough, E.C., 725
McDonald, A., 965
McDonald, J., 1073
McDonald, S., 99
McIntyre, T.M., 627
McKhann, C., 53
McLaughlin, P.W., 761, 797
McShan, D.L., 1061, 1139, 1159, 1173, 1181
Meijer, O.W.M., 635
Mella, O., 409
Mendenhall, W.M., 549, 563
Menke, M., 455
Mesina, C.F., 1321
Metreweli, C., 919
Meyers, C.A., 179
Meyn, R.E., 781
Michalski, J., 1041, 1301
Michalski, J.M., 831, 985
Mieler, W.F., 659
Million, R.R., 89
Miquéliz, S., 675
Miyasaka, K., 323
Mohan, R., 1081, 1101, 235
Mohiuddin, M., 937
Morrill, S.M., 1091
Morrison, W.H., 289, 479, 549, 563
Mosseri, V., 271
Movsas, B., 599
Movsas, T.Z., 599
Mundt, A.J., 261, 1001
Munheer, B.J., 1265
Munzenrider, J.E., 579
Murata, R., 119
Murray, T.G., 659
Myint, S., 549, 563

Nademanee, A., 189
Naftel, D.C., 83
Nakano, M., 843
Nash, R.N., 659
Nautiyal, J., 261, 607
Nestle, U., 349
Ney, D.R., 1029
Nickens, J.A., 179
Nieder, C., 349
Niewald, M., 349
Nikolic, M., 469
Nixon, A.J., 245
Nondahl, D.M., 509
Nouet, P., 211, 713

Oberman, H.A., 253
Ochran, T.G., 725
Oetzel, D., 455
O'Fallon, J.R., 663
Ohanian, N., 161
Ohmura, M., 135
Okunieff, P., 599, 961
O'Neill, B.P., 663
Orrison, W., 705
Orsatti, M., 173
Ostwald, P.M., 943
O'Sullivan, B., 549, 563, 689
Overett, T.K., 429
Owen, J., 803
Owen, J.B., 519, 549, 563
Oya, N., 119
Ozsahin, M., 951

Paliwal, B.R., 659
Palta, J.R., 725

Papirov, I., 211, 713
Parker, D.L., 823
Parker, R.G., 375
Parsons, C., 469
Parsons, J.T., 89, 549, 563
Peacock, J.L., 969
Peiffert, D., 447
Pelizzari, C.A., 1221, 1321
Pene, F., 951
Perez, C., 823
Perez, C.A., 831
Pernot, M., 447
Peters, L.J., 289, 479, 549, 563
Peters, T.L., 549, 563
Peterson, L.M., 391
Pezner, R.D., 189
Phil, D., 855
Phillips, T.L., 339
Pierce, L.J., 253
Pilepich, M.V., 823
Pisch, J., 183
Pizarro, A., 329
Pizzuto, D., 1101
Plunkett, M., 1019
Point, D., 271
Pollack, A., 23, 907
Pollock, B.E., 437
Popowski, Y., 211, 713
Potters, L., 851
Prosnitz, L.R., 37, 65, 963
Purdy, J., 1301
Purdy, J.A., 1195, 985, 993

Raghavan, S., 1287
Rana, V.G., 329
Rasey, J.S., 391
Raue, F., 307
Ray, P., 1009
Raymond, M.G., 329
Recht, A., 245
Reeves, J.A., 329
Reiff, J.E., 937
Rezvani, M., 509
Rich, T.A., 913
Roach, M., III, 15
Robertson, C.N., 37
Robinson, S. P., 855
Rodriguez, J., 271
Rodriguez, L., 357
Roeske, J.C., 1321
Rosen, I.I., 1091
Rosenberg, A.E., 585
Rosenman, J., 1041
Rosenthal, S.J., 1239
Roszinski, S., 409
Rotman, M., 339, 901
Rousseau, J., 201
Rouzaud, M., 211, 713
Rubenstein, J.H., 329
Rubin, P., 99, 823
Rubin, S.J., 3, 1221
Rush, S., 851
Rutishauser, W., 211, 713

Sacchini, V., 59
Sakumoto, K., 843
Salenius, S.A., 329
Salter, M.M., 83
Salter, S.P., 83
Sandler, H.M., 1281, 797
San Galli, F., 315
Sasai, K., 119
Sause, W.T., 823
Sawaya, R., 357
Saxena, V.S., 683
Scarpati, D., 173
Schem, B.-C., 409
Schmidt-Ullrich, R.K., 281
Schmidt-Ullrich, R.K.A., 931
Schnabel, K., 349
Schraube, P., 455
Schreiber, D.P., 429
Schultheiss, T., 837
Schultheiss, T.E., 217, 549, 563
Schultz, D.J., 45
Schwager, M., 211, 713
Schwartz, L.H., 951
Scott, C., 901
Scott, C.B., 339
Seong, J., 869
Shaer, A.H., 925
Shao, Y., 417
Shapiro, C., 1001
Shaw, J.E., 195
Sherman, N.E., 1127
Sherouse, G.W., 65, 1209
Shibamoto, Y., 119
Shibata, T., 119
Shin, D.M., 179
Shirato, H., 323
Shouman, T., 1109, 1311
Shrieve, D.C., 531, 765
Sibley, G., 261
Sibley, G.S., 1001
Siemann, D.W., 365
Silver, B., 245
Singh, S., 129
Smathers, J.B., 375
Smith, A.R., 519, 803
Smith, R., 53
Socié, G., 881
Söderström, S., 151
Soen, J., 725
Soimakallio, S., 719
Solin, L.J., 45
Sombeck, M.D., 89
Song, P.Y., 1121
Song, S.-Y., 417
Sørensen, P.S., 595
Speer, T.W., 89
Spelbring, D., 1009
Spelbring, D.R., 1121
Spencer, D.P., 65
Spencer, D.P., 627, 1209
Spencer, W., 161
Spiro, I.J., 585
Sroka-Pérez, G., 455

Stamey, T.A., 967
Starkschall, G., 1127, 479
Stea, B., 461
Steeves, R.A., 659
Steinberg, S.M., 599
Stephens, L.C., 529
Stock, R.G., 815
Stone, N.N., 815
Strawderman, M.H., 253
Stromberg, J., 1019, 161
Suh, C.O., 869
Sun, J., 1331
Sun, J.-R., 619
Suntharalingam, N., 937
Sur, R.K., 985
Sutton, H., 607
Sutton, H.G., 3
Suzuki, M., 135
Suzuki, T., 119
Svoboda, V., 549, 563
Sweeney, P., 3, 1221

Tabata, T., 695
Takagi, T., 119
Tan, L.T., 195
Tartour, E., 881
Tatsuzaki, H., 135
Taylor, J.M.G., 549, 563
Taylor, R., 1229
Teale, B., 129
Tejedor, M., 675
Ten Haken, R.K., 1281, 797
Tenhunen, M., 719
Teo, P.M.L., 569
Teshima, T., 809
Teufel, T.E., 329
Thall, A., 1287
Thall, P.F., 357
Thames, H.D., 281, 755
Thompson, M., 549, 563
Thornton, A.F., Jr., 1239
Toita, T., 843
Tompkins, D.T., 659
Touw, A., 1109, 1311
Trouette, R., 315
Turner, D., 1209

Unger, J., 1073
Unger, P., 815
Urban, P., 211, 713
Usenius, J.-P., 719
Usenius, T., 719

Vaida, F., 1009, 607
Vainio, P., 719
Valerdi, J.J., 675
van den Berg, J., 635
Van den Bogaert, W., 499
Vandevelde, G., 499
van Dyk, J., 549, 563
van Herk, M., 1109, 1265, 1311
Vann, K., 65
van Rijn, J., 635
Vasseur, C., 201
Venturini, M., 173
Verdi, C., 461
Verin, V., 211, 713
Vicini, F., 1019, 1229, 1247, 161
Vijayakumar, S., 1001, 1009, 1121, 607, 979
Vikram, B., 183
Villafranca, E., 675
Vitale, V., 173
von Eschenbach, A.C., 23
Voss, N.J.S., 469

Wallace, M., 519, 803
Walter, K., 349
Wang, C.C., 549, 563, 585
Wang, H.-J., 641
Wannenmacher, M., 307
Ward, B., 53
Ward, S.C., 919
Wasserman, T.H., 965
Watkins-Bruner, D., 901
Weaver, R.D., 475
Weaver, T.A., 1139, 1159, 1181
Weichselbaum, R., 1001
Weichselbaum, R.R., 3, 261
Weigensberg, I.J., 339
Weltens, C., 499
Willcut, V., 1195
Willers, H., 585
Williams, J.P., 99
Williams, J.R., 417
Williams, S., 261
Wilson, L.D., 53
Withers, H.R., 375, 549, 563, 619
Wong, J., 1229, 1247, 1301
Wong, J.W., 1273
Wong, P.-F., 479
Woo, S., 357
Wu, N.Z., 627
Würschmidt, F., 77

Yahalom, J., 525
Yan, D., 1019, 1229, 1247, 1257, 1301, 161
Yang, F.E., 607, 1009
Yang, L.-X., 641
Yatagai, F., 135
Yeh, K.A., 111
Yeo, W., 569
Yu, C., 1229, 1273
Yung, W.K.A., 357

Zagars, G.K., 23, 907
Zhang, Y.G., 417
Zhou, R., 823
Zhu, J.G., 647
Zierhut, D., 307
Zucali, R., 59
Zwicker, R.D., 931

SUBJECT INDEX

Volume 33, 1995

A

Accelerated fractionation, 289
Accelerated fractionated radiotherapy, 357
Accelerated tumor growth, 549
ACNU, 409
Acromegaly, 307
Acute phase response, 619
Adaptive response, 869
Adenocarcinoma of the prostate, 925
Adjunctive chemotherapy, 569
Adjuvant therapy, 37
Ammonium, 143
Androgen ablation, 823, 907
Angioplasty, 211
Angiosarcoma, 585
Anoxia, 365
Antiviral agents, 861
Apoptosis, 781
Atomic absorption spectrometry, 641
Autologous bone marrow transplantation, 189, 261
Automated treatments, 1159
Axillary recurrence, 253

B

Base of skull, 579
Base-of-tongue, 289
Beam scatterer-degraders, 469
Beam's eye view, 1001
Beam's-eye view, 1061
Biologically effective dose (BED), 375
Bladder cancer, 173
Bladder preservation, 173
Blood flow, 855
Bone marrow toxicity, 607
Bone marrow transplantation, 881
Brachytherapy, 1257, 195, 211, 447, 659, 713, 851
Brain, 619, 719
Brain metastases, 339, 349
Brain tumors, 1209
BrdUrd, 339
Breast cancer, 45, 59, 245, 253, 683
Breast-conservation treatment, 45
Buccal mucosa, 447
Build-up characteristics, 951

C

^{60}C Unit, 951
Calcitonin gene-related peptide, 297
Carbogen, 855
Carbon-ions, 135
Carbon-loaded TLDs, 943
Carboplatin, 357, 641
Carcinoma, 329
Carcinoma of tonsil, 549, 563
Cardiac transplantation, 83
Cell proliferation, 635
Cell survival, 135, 635
Centering, 713
Cerrobend block, 1247
Cervical spine, 579
Cervix neoplasms, 843
Cheek, 447
Chordoma, 579
Choroidal melanoma, 659
Chromatid breaks, 869
Chromosome aberrations, 781
Cisplatinum, 429
Classification, 77
Clinical radiobiology, 281
Clinical target volume, 1073
Clinical trials, 747
Clonogenic survival, 781
Clonogens, 281
Collision avoidance, 1101
Collision detection, 1173
Colon carcinoma, 417
Combined initial therapy, 663
Combined modality treatment, 77, 173
Complete blood counts, 607
Complication-free control, 151
Complications, 563
Computed tomography, 1029, 281, 349, 843
Computer assisted, 1181
Computer-assisted, 797
Computer control, 1101, 1159, 1181
Computer-control, 1139
Computer-controlled, 1173
Computer controlled multileaf collimator, 1247
Concomitant boost, 289
Concomitant cisplatin, 675
Conformal, 1209, 1257, 985
Conformal brachytherapy, 161
Conformal radiation therapy, 15, 1073, 1091, 1109
Conformal radiotherapy, 1001, 1041, 1121, 1273, 1311, 979
Conformal therapy, 1009, 1019, 1061, 1139, 1159, 1173, 1181, 1195, 1221, 1281, 1321
Conservative surgery, 59, 245
Conservative surgery and radiation therapy, 53
Cosmesis, 59
Costs, 499
Craniopharyngioma, 437
CTV, 1041
Cytokine cascade, 99
Cytokines, 619

D

Daily setup variation, 1301
Database, 1181
Differentiation, 875
Digital simulation, 931
Digitally reconstructed radiographs, 1053
Disease-free interval, 189
DNA binding protein, 129
DNA damage, 875
DNA repair, 781
Dose, 509
Dose distribution, 375
Dose-fractionation, 549
Dose fractionation, 563
Dose-response relationship, 217, 349
Dose-surface histogram, 1121
Dose-volume histogram, 65, 455
Dose-volume histograms, 1109
Dosimetric consequences, 1331
Dosimetry, 1195, 1265, 417, 683, 951
Dosimetry of large fields, 493

E

Elderly women, 45
Electron backscattering, 695
Electron bolus, 1127, 479
Electron cone, 695
Electron conformal radiotherapy, 1127
Electron dosimetry, 479
Electronic chart, 1139, 1181
Electronic portal imaging devices, 1053
Electrons, 725
Endobronchial, 195
Endometrial cancer, 837, 851
Epidermoid carcinoma, 447
External auditory canal, 479
Extracapsular extension, 253

F

Fast neutrons, 135
Ferromagnetic hyperthermia, 659
Fibrosis, 99
Field size, 563
Film dosimetry, 1229
[F-18]fluoromisonidazole, 391
Fluoroscopic, 1273
Fractionated, 1209
Fractionated radiation therapy, 315
Fractionated radiotherapy, 1239
Fractionation, 281, 509
Fraction number, 509
Fraction size, 509
Functional, 65
Functional MRI, 855

G

Gadolinium-DTPA, 485
Gamma rays, 869
Gene therapy, 861
Giant cell tumor of bone, 689

Glioblastoma, 357
Glucose, 409
Grid therapy, 937
Growth kinetics, 549
GTV, 1041

H

Headaches, 599
Head and neck, 509, 585
Head and neck cancers, 675
Head and neck carcinomas, 271
Head and neck neoplasms, 281
Head and neck tumors, 499
Hepatic irradiation, 913
Hepatic tumors, 919
Herpes simplex virus, 861
High-dose effects, 217
High dose rate, 161
High dose rate brachytherapy, 1019, 931
High Z interface, 695
Histograph, 111
Hodgkin's Disease, 189, 261, 519
Hormonal cytoreduction, 1009
Hormone refractory, 907
Hydralazine, 143
Hyperfractionated radiation, 183
Hyperfractionated radiotherapy, 675
Hyperthermia, 409, 429, 887
Hypoxia, 111
Hypoxic cell radiosensitizer, 119

I

Image alignment, 1053
Image analysis, 823
Image correlation, 1053
Image processing, 1029
Image registration, 1287, 1311, 1321, 1331
Immobilization devices, 499
Impotence, 15
Inflammation, 627
Intensity modulation, 1139
Interstitial, 429
Interstitial iridium-192 implantation, 161
Intracavitary irradiation, 437
Intracavitary treatment, 695
Intraoperative, 1257
Intraoperative care, 725
In vivo dosimetry, 1265
Involved-field radiation therapy, 261
Ionization chamber, 1265
Iridium-192, 429
Irradiation, 297, 307, 641

K

Kilovoltage, 1273

L

9L glioma cells, 861
Laparoscopic pelvic lymph node dissection, 815
Larynx, 509
Lens, 705
Leukocyte-endothelial cell interaction, 627
Limited disease, 77
Linear accelerator, 485
Linear accelerators, 225
Linear-quadratic, 375
Linear quadratic, 509
Local control, 585
Localization of the prostatic apex, 925
Local recurrence, 245
Long-term results, 689
Lung, 179
Lung cancer, 183, 195, 455, 993
Lung compensators, 493
Lung neoplasms, 329
Lung perfusion, 65
Lung shunting, 919
Lung tumor, 635
Lymphatic metastasis, 843
Lymphocyte radiosensitivity, 881

M

Magnetic resonance imaging, 485
Malignant glioma, 461
Mandibular necrosis, 563
Marker, 705
Meningiomas, 315
Mixed beam, 3
Mixture models, 281
MLC, 1195
Motion analysis, 1239
Moving beam therapy, 493
Multiarc radiosurgery, 647
Multicellular spheroids, 135
Multileaf collimation, 1081, 1195
Multileaf collimator, 1159, 1181, 1195, 1229
Multileaf collimators, 1139
Multiple epidural metastases, 595
Mycosis fungoides, 475

N

Nasopharyngeal carcinoma, 569
Necrosis, 781
Neoadjuvant hormonal therapy, 1009
Neoplasm recurrence, 89, 843
Neoplasms, 725
Neuropetide Y, 297
Neuropsychologic function, 179
Neurovascular, 599
Neutrons, 3, 129
Nonlinear simplex optimization, 647
Nonsmall cell lung cancer, 1001
Normalized isoeffective dose (NID), 375
Normal tissue, 627
Normal tissue complication probability (NTCP), 455, 1121
Nuclear magnetic resonance spectroscopy, 719

O

Ocular globe, 705
Ocular hyperthermia, 659
Olfactory bulb, 705
Optimal beam portals, 151
Optimization, 1061, 1091, 1257, 201, 217
Organ motion, 1311
Osteosarcoma cells, 135
Outcome analysis, 549
Overall time, 509
Oxygenation, 855
Oxygen electrode, 111
Oxygen measurement, 365

P

^{31}P and ^{14}N NMR, 143
Paget's disease, 53
Pancreatic cancer, 913
Pancreaticoduodenectomy, 913
Patient alignment, 1239
Patient safety, 1101
Patient setup analysis, 1287
Patterns of care, 519, 803, 809
Patterns of failure, 245
PCNSL, 663
PCV, 357
Pediatric neoplasms, 985
Penumbra, 1195, 1229
Persistence, 99
pH, 409
Pharynx, 509
Phosphorus-32, 437
Photon beam dosimetry, 937
Photoneutrons, 225
Pituitary adenoma, 307
Pituitary tumor, 599
Planning target volume, 1073
Platelet-activating factor, 627
Platinum uptake, 641
PLDR, 135
Pneumonitis, 99, 455
pO_2, 111
Portal images, 1287
Portal imaging, 1265, 1273, 1281, 1301, 1331
Positron emission tomography, 391
Potency, 15
PR-350 series, 119
Pretreatment PSA, 809
Prognostic factor, 843
Prognostic factors, 23, 77, 585
Prognostic parameters, 887
Prolactinoma, 307
Prophylactic cranial irradiation, 179, 329
Prostate, 803
Prostate cancer, 15, 23, 37, 1009, 1109, 1121, 1257, 809, 815, 823, 901, 907
Prostate carcinoma, 1019, 111, 161
Prostate irradiation, 1311
Prostate motion, 1321
Prostate movement, 1281
Prostate neoplasms, 3
Prostate specific acid phosphatase, 823
Prostate-specific antigen, 23, 161
Prostatic neoplasms, 797
Proton, 1239
Proton therapy, 579
PTV, 1041, 1073

Q

Quality assurance, 1265, 499
Quality of life, 901
Quantification, 719

R

Radiation, 579, 619, 627, 635, 781, 851
Radiation activation, 129
Radiation dose response, 549
Radiation effects, 719
Radiation-induced aplasia, 881
Radiation oncology, 519
Radiation pneumonitis, 919
Radiation sensitizer, 861
Radiation therapy, 3, 23, 45, 1091, 1101, 1209, 189, 253, 349, 461, 549, 599, 719, 747, 815, 831, 837, 887
Radiation Therapy Oncology Group, 747
Radiation treatment planning, 65
Radiation treatment time factors, 837
Radiocordectomy, 323
Radioimmunotherapy, 417
Radiopotentiation, 641
Radiosensitivity, 875
Radiosensitizing effect, 119
Radiosurgery, 201, 461
Radiotherapy, 37, 59, 77, 89, 1181, 1265, 1287, 161, 245, 271, 281, 289, 307, 323, 339, 391, 499, 509, 683, 689, 725, 781, 797, 843, 855, 907, 979, 985
Radiotherapy simulation, 931
Radiotherapy toxicity, 607
Randomized, 509
Rat brain, 485
Recurrent breast cancer, 887
Regression analysis, 683
Rejection, 83
Relapsed/refractory, 261
Restenosis, 211, 713
Retina, 705
Retinoic acid, 875
RIF-1, 143

S

Salivary gland, 297
Sarcoma of paraspinal muscles, 1127
Second malignancies, 225
Second malignancy, 831
Second spinal cord compression, 595
Segmental therapy, 1061
Seminal vesicle biopsy, 815
Seminoma, 89, 831
Setup error analysis, 1301
Sexual dysfunction, 15
Sexual function, 901
Shielding, 705
Simulated annealing, 1091
Simulation, 1173, 705
Simultaneous chemotherapy, 183
Skin dose, 943
Small cell, 329
Small cell carcinoma, 179
Small cell lung cancer, 77
SOBP, 135
Soft tissue sarcoma, 585
SPECT, 65
Spinal cord glioma, 323
Stage III, 1001
Stanford technique, 469
Stereotactic radiosurgery, 1221, 485
Stereotactic radiotherapy, 1221, 1239
Stereotaxy, 201
Subareolar breast cancer, 53
Substance P, 297
Superficial treatment, 695
Superior vena cava syndrome, 77
Surgery, 725
Surgical simulation, 1029
Survival, 3, 77, 823
SW1573 cell, 635

T

Target, 1041
Taxol, 635
Testicular carcinoma, 831
Testicular neoplasms, 89
Thermal dosimetry, 887
Thermoluminescent dosimetry, 475, 943
Thermoradiotherapy, 659
3D conformal treatment planning, 925
3D planning, 1239
3D treatment planning, 1061
Three-dimensional conformal radiotherapy, 1053
Three dimensional conformal therapy, 1081
Three-dimensional imaging, 1029
Three-dimensional radiation therapy, 979
Three dimensional treatment planning, 1073, 1127
Three-dimensional treatment planning, 993
Thymidine kinase, 861
Time, 509
Tolerance limits, 217
Topography, 705
Total body irradiation, 493, 881, 951
Total dose, 509
Total lymphoid irradiation, 83
Total skin electron irradiation, 469
Total skin irradiation, 475
Toxicity, 119
Transmission dosimetry, 1265
Transurethral prostatectomy, 15
Treatment delivery, 1139, 1173
Treatment optimization, 151
Treatment planning, 1081, 1091, 1257, 195, 201, 519, 683, 803
Treatment setup variation, 1247
Treatment verification, 1053, 1139, 1287, 1301
Tumor, 1029, 1041
Tumor control, 887
Tumor hypoxia, 365, 391
Tumor oxygenation, 111, 365, 391
Tumor regression local control relationships, 271
Tumor size, 843
Tumor volume, 281

U

Ultrasound guidance, 1019, 161
Urinary function, 901

V

Verification, 1159, 1173
Virtual simulation, 1053
Vision, 599

X

Xenograft, 417

Y

^{90}Y, 713
Yttrium-90, 417
^{90}Yttrium-microspheres, 919